Program 14-15 September
Translating PKPD – (retro)perspectives
- Download Program (final)
14 SEPTEMBER 2022
12:00–13:00 Registration
13:00–15:00 Opening remarks
Translating PKPD - (Retro)perspectives
Margareta Hammarlund-Udenaes, Uppsala University (SE)
Session 1: Building highways for PKPD
Discussion leader: David Smith, University of Michigan (US)
From strategic microdialysis experiments to predictive mathematical models
Elizabeth CM de Lange, Leiden University (NL)
Transporter protein quantification of the CNS barriers for the understanding of Kp,uu,brain
Tetsuya Terasaki, University of Eastern Finland (FI) and Tohoku University (J)
PK/PD/Efficacy translational modeling in brain tumors
William F Elmquist, Minnesota University (US)
Pharmacometrics, PBPK, QSP, What’s Next?
Stephan Schmidt, University of Florida (US)
15:00–15:30 Coffee/Tea break/Poster session
15:30–17:30
Session 2: Mapping PKPD of new drug modalities
Discussion leader: Dag Sehlin, Uppsala University (SE)
Routes and crossroads for development and delivery of biologic therapies for diseases of the CNS
Danica Stanimirovic, National Research Council of Canada (CAN)
Importance and utilization/application of PKPD during drug development
Gunilla Osswald, BioArctic (SE)
Translational PK/PD and model-informed clinical development of AZD8233 - a subcutaneously administered PCSK9 antisense-oligonucleotide
Jane Knöchel, AstraZeneca (SE)
Microdialysis to investigate antibody brain delivery
Stina Syvänen, Uppsala University (SE)
19:00–22:00 Dinner (Pharmen, Uppsala)
15 SEPTEMBER 2022
9:00–10:30
Session 3: Revolutionizing PKPD tools in drug discovery and development
Discussion leader: Edmund Hoppe, Boehringer Ingelheim (DE)
Translational PKPD is an efficient and impactful tool in the discovery and development of drugs
Rasmus Jansson-Löfmark, AstraZeneca (SE)
Links between cellular drug concentrations and drug response
Per Artursson, Uppsala University (SE)
Interplay in blood-brain barrier transport in vivo – Deliver the goods or get carried away?
Christoffer Bundgaard, Lundbeck (DK)
Unraveling target-site drug disposition: key to understand the PK/PD of chemotherapy-induced peripheral neuropathy
Yang Hu, Boehringer Ingelheim (AU)
10:30–11:00 Coffee/Tea break/Poster session
11:00–12:30
Session 4: Bringing PKPD closer to patients
Discussion leader: Marie Gårdmark, RegSmart LifeScience AB (SE)
Lung pharmacokinetics of inhaled and systemic drugs– evaluation of regional lung targeting by direct sampling of epithelial lining fluid
Muhammad Waqas Sadiq, AstraZeneca (SE)
Model-Informed Precision Dosing at the Bedside: Challenges and Opportunities
Elisabet Nielsen, Uppsala University (SE)
Bridging the dynamics in the forecast of dosing strategies
Lena Friberg, Uppsala University (SE)
Quantifying CNS disease and therapeutic effects – a focus on composite score analyses
Mats Karlsson, Uppsala University (SE)
12:30–13:30 Lunch
13:30–15:00
Session 5: Panel discussion: “Will we need to continue developing experimental PKPD toolboxes in the future or will in silico predictions drive the area forward?”
Moderator: Markus Fridén, AstraZeneca & Uppsala University (SE)
Continuous success in creating medicines of established drug modalities - small molecules and monoclonal antibodies - has been enabled by comprehensive understanding of PK and PK/PD and the availability of industrial infrastructures for discovery and development. In this panel discussion we explore the challenges ahead for successfully delivering medicines of the whole plethora of new modalities and targeted delivery approaches. How can we leverage established PK and PK/PD methodologies and what are the areas in need of innovation?
Presenter 1: Elizabeth CM de Lange, Leiden University (NL)
Presenter 2: Lassina Badolo, AstraZeneca (SE)
Presenter 3: Irena Loryan, Uppsala University (SE)
Presenter 4: Pär Matsson, University of Gothenburg (SE)
Panel discussion Closing remarks
15:00–15:30 Coffee/Tea break/Mingle